WO2001016176A3 - Transgenic animal model for neurodegenerative diseases - Google Patents

Transgenic animal model for neurodegenerative diseases Download PDF

Info

Publication number
WO2001016176A3
WO2001016176A3 PCT/EP2000/008071 EP0008071W WO0116176A3 WO 2001016176 A3 WO2001016176 A3 WO 2001016176A3 EP 0008071 W EP0008071 W EP 0008071W WO 0116176 A3 WO0116176 A3 WO 0116176A3
Authority
WO
WIPO (PCT)
Prior art keywords
neurodegenerative diseases
transgenic animal
human
animal model
sequence
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Ceased
Application number
PCT/EP2000/008071
Other languages
French (fr)
Other versions
WO2001016176A2 (en
Inventor
Hermann Luebbert
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Biofrontera Bioscience GmbH
Original Assignee
Biofrontera Pharmaceuticals GmbH
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Biofrontera Pharmaceuticals GmbH filed Critical Biofrontera Pharmaceuticals GmbH
Priority to ES00956461T priority Critical patent/ES2304973T3/en
Priority to DE60038966T priority patent/DE60038966D1/en
Priority to CA002383564A priority patent/CA2383564A1/en
Priority to JP2001520735A priority patent/JP2003512026A/en
Priority to EP00956461A priority patent/EP1208200B1/en
Publication of WO2001016176A2 publication Critical patent/WO2001016176A2/en
Publication of WO2001016176A3 publication Critical patent/WO2001016176A3/en
Anticipated expiration legal-status Critical
Ceased legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N9/00—Enzymes; Proenzymes; Compositions thereof; Processes for preparing, activating, inhibiting, separating or purifying enzymes
    • C12N9/93—Ligases (6)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K49/00—Preparations for testing in vivo
    • A61K49/0004—Screening or testing of compounds for diagnosis of disorders, assessment of conditions, e.g. renal clearance, gastric emptying, testing for diabetes, allergy, rheuma, pancreas functions
    • A61K49/0008—Screening agents using (non-human) animal models or transgenic animal models or chimeric hosts, e.g. Alzheimer disease animal model, transgenic model for heart failure
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
    • C12N15/79—Vectors or expression systems specially adapted for eukaryotic hosts
    • C12N15/85—Vectors or expression systems specially adapted for eukaryotic hosts for animal cells
    • C12N15/8509—Vectors or expression systems specially adapted for eukaryotic hosts for animal cells for producing genetically modified animals, e.g. transgenic
    • A—HUMAN NECESSITIES
    • A01—AGRICULTURE; FORESTRY; ANIMAL HUSBANDRY; HUNTING; TRAPPING; FISHING
    • A01K—ANIMAL HUSBANDRY; AVICULTURE; APICULTURE; PISCICULTURE; FISHING; REARING OR BREEDING ANIMALS, NOT OTHERWISE PROVIDED FOR; NEW BREEDS OF ANIMALS
    • A01K2207/00—Modified animals
    • A01K2207/15—Humanized animals
    • A—HUMAN NECESSITIES
    • A01—AGRICULTURE; FORESTRY; ANIMAL HUSBANDRY; HUNTING; TRAPPING; FISHING
    • A01K—ANIMAL HUSBANDRY; AVICULTURE; APICULTURE; PISCICULTURE; FISHING; REARING OR BREEDING ANIMALS, NOT OTHERWISE PROVIDED FOR; NEW BREEDS OF ANIMALS
    • A01K2217/00—Genetically modified animals
    • A—HUMAN NECESSITIES
    • A01—AGRICULTURE; FORESTRY; ANIMAL HUSBANDRY; HUNTING; TRAPPING; FISHING
    • A01K—ANIMAL HUSBANDRY; AVICULTURE; APICULTURE; PISCICULTURE; FISHING; REARING OR BREEDING ANIMALS, NOT OTHERWISE PROVIDED FOR; NEW BREEDS OF ANIMALS
    • A01K2217/00—Genetically modified animals
    • A01K2217/05—Animals comprising random inserted nucleic acids (transgenic)
    • A—HUMAN NECESSITIES
    • A01—AGRICULTURE; FORESTRY; ANIMAL HUSBANDRY; HUNTING; TRAPPING; FISHING
    • A01K—ANIMAL HUSBANDRY; AVICULTURE; APICULTURE; PISCICULTURE; FISHING; REARING OR BREEDING ANIMALS, NOT OTHERWISE PROVIDED FOR; NEW BREEDS OF ANIMALS
    • A01K2217/00—Genetically modified animals
    • A01K2217/07—Animals genetically altered by homologous recombination
    • A01K2217/075—Animals genetically altered by homologous recombination inducing loss of function, i.e. knock out
    • A—HUMAN NECESSITIES
    • A01—AGRICULTURE; FORESTRY; ANIMAL HUSBANDRY; HUNTING; TRAPPING; FISHING
    • A01K—ANIMAL HUSBANDRY; AVICULTURE; APICULTURE; PISCICULTURE; FISHING; REARING OR BREEDING ANIMALS, NOT OTHERWISE PROVIDED FOR; NEW BREEDS OF ANIMALS
    • A01K2267/00—Animals characterised by purpose
    • A01K2267/03—Animal model, e.g. for test or diseases
    • A—HUMAN NECESSITIES
    • A01—AGRICULTURE; FORESTRY; ANIMAL HUSBANDRY; HUNTING; TRAPPING; FISHING
    • A01K—ANIMAL HUSBANDRY; AVICULTURE; APICULTURE; PISCICULTURE; FISHING; REARING OR BREEDING ANIMALS, NOT OTHERWISE PROVIDED FOR; NEW BREEDS OF ANIMALS
    • A01K2267/00—Animals characterised by purpose
    • A01K2267/03—Animal model, e.g. for test or diseases
    • A01K2267/0306—Animal model for genetic diseases
    • A01K2267/0318—Animal model for neurodegenerative disease, e.g. non- Alzheimer's

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Genetics & Genomics (AREA)
  • Engineering & Computer Science (AREA)
  • Chemical & Material Sciences (AREA)
  • Zoology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Organic Chemistry (AREA)
  • Biomedical Technology (AREA)
  • Wood Science & Technology (AREA)
  • General Health & Medical Sciences (AREA)
  • General Engineering & Computer Science (AREA)
  • Biotechnology (AREA)
  • Biochemistry (AREA)
  • Molecular Biology (AREA)
  • Microbiology (AREA)
  • Veterinary Medicine (AREA)
  • Pathology (AREA)
  • Urology & Nephrology (AREA)
  • Biophysics (AREA)
  • Diabetes (AREA)
  • Endocrinology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Plant Pathology (AREA)
  • Rheumatology (AREA)
  • Toxicology (AREA)
  • Physics & Mathematics (AREA)
  • Epidemiology (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Investigating Or Analysing Biological Materials (AREA)
  • Peptides Or Proteins (AREA)
  • Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)

Abstract

The present application refers to a mouse parkin2 DNA- and protein sequence, containing mutations or deletions causing Parkinson's disease in a human if occurring in the according human sequence, the construction of a transgenic non-human animal containing such a mutated DNA sequence and therefore expressing no or a less active or non-active parkin protein as well as the use of this transgenic animal as a model for neurodegenerative diseases.
PCT/EP2000/008071 1999-08-30 2000-08-18 Transgenic animal model for neurodegenerative diseases Ceased WO2001016176A2 (en)

Priority Applications (5)

Application Number Priority Date Filing Date Title
ES00956461T ES2304973T3 (en) 1999-08-30 2000-08-18 TRANSGENIC ANIMAL MODEL FOR NEURODEGENERATIVE DISEASES.
DE60038966T DE60038966D1 (en) 1999-08-30 2000-08-18 Transgenic animal model for neurodegenerative diseases
CA002383564A CA2383564A1 (en) 1999-08-30 2000-08-18 Transgenic animal model for neurodegenerative diseases
JP2001520735A JP2003512026A (en) 1999-08-30 2000-08-18 Transgenic animal models for neurodegenerative diseases
EP00956461A EP1208200B1 (en) 1999-08-30 2000-08-18 Transgenic animal model for neurodegenerative diseases

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
EP99116766.9 1999-08-30
EP99116766A EP1081225A1 (en) 1999-08-30 1999-08-30 Transgenic animal model for neurodegenerative diseases

Publications (2)

Publication Number Publication Date
WO2001016176A2 WO2001016176A2 (en) 2001-03-08
WO2001016176A3 true WO2001016176A3 (en) 2001-09-27

Family

ID=8238860

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/EP2000/008071 Ceased WO2001016176A2 (en) 1999-08-30 2000-08-18 Transgenic animal model for neurodegenerative diseases

Country Status (7)

Country Link
EP (2) EP1081225A1 (en)
JP (1) JP2003512026A (en)
AT (1) ATE396263T1 (en)
CA (1) CA2383564A1 (en)
DE (1) DE60038966D1 (en)
ES (1) ES2304973T3 (en)
WO (1) WO2001016176A2 (en)

Families Citing this family (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
FR2845245A1 (en) * 2002-10-07 2004-04-09 Aventis Pharma Sa Transgenic animal model of Parkinson's disease, useful in screening for agents effective against neurodegenerative diseases, contains a parkin gene with a deletion in exon 3
US6943278B2 (en) * 2002-10-15 2005-09-13 Genexel, Inc. Transgenic Drosophila having a disrupted Parkin gene and exhibits reduced climbing ability
CN113373150B (en) * 2021-06-18 2022-11-22 南方科技大学 sgRNA of targeting dat gene and application thereof

Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1998059050A1 (en) * 1997-06-25 1998-12-30 The Government Of The United States Of America Represented By The Secretary, Department Of Health And Human Services Cloning of a gene mutation for parkinson's disease
WO1999040191A1 (en) * 1998-02-09 1999-08-12 Boehringer Ingelheim International Gmbh Dnas or genes participating in parkinson's disease
WO2000031253A2 (en) * 1998-11-19 2000-06-02 Aventis Pharma S.A. Mutation of the parkin gene, compositions, methods and uses

Patent Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1998059050A1 (en) * 1997-06-25 1998-12-30 The Government Of The United States Of America Represented By The Secretary, Department Of Health And Human Services Cloning of a gene mutation for parkinson's disease
WO1999040191A1 (en) * 1998-02-09 1999-08-12 Boehringer Ingelheim International Gmbh Dnas or genes participating in parkinson's disease
WO2000031253A2 (en) * 1998-11-19 2000-06-02 Aventis Pharma S.A. Mutation of the parkin gene, compositions, methods and uses

Non-Patent Citations (10)

* Cited by examiner, † Cited by third party
Title
ABBAS ET AL: "A wide variety of mutations in the parkin gene are responsible for autosomal recessive parkinsonism in Europe", HUMAN MOLECULAR GENETICS,GB,OXFORD UNIVERSITY PRESS, SURREY, vol. 8, no. 4, April 1999 (1999-04-01), pages 567 - 574, XP002108471, ISSN: 0964-6906 *
DALIE J E (PROGRAM MANAGER - SOCIETY FOR NEUROSCIENCE): "Publication dates for the 1999 Abstract Volumes", SOCIETY FOR NEUROSCIENCE ABSTRACTS, 16 August 1999 (1999-08-16), XP002157614 *
DATABASE EMROD E.M.B.L. Databases; 13 July 1999 (1999-07-13), SHIMIZU N ET AL: "Mus musculus mRNA for parkin, complete cds", XP002131476 *
GOLDBERG M S ET AL: "STUDIES OF WILD-TYPE AND MUTANT ALPHA-SYNUCLEIN IN TRANSGENIC MICE", ANNUAL MEETING SOCIETY NEUROSCIENCE,XX,XX, vol. 24, no. 1/02, 1998, pages 966, XP000884112 *
HATTORI ET AL: "Point Mutations (Thr240Arg and Ala311Stop) in the Parkin Gene", BIOCHEMICAL AND BIOPHYSICAL RESEARCH COMMUNICATIONS,US,ACADEMIC PRESS INC. ORLANDO, FL, vol. 249, no. 3, 1998, pages 754 - 758, XP002108468, ISSN: 0006-291X *
HATTORI N ET AL: "Molecular genetic analysis of a novel Parkin gene in Japanese families with autosomal recessive juvenile parkinsonism: evidence for variable homozygous deletions in the Parkin gene in affected individuals", ANN NEUROL., vol. 44, no. 6, December 1998 (1998-12-01), pages 935 - 941, XP000877155 *
KESSLER J ET AL: "Investigation of the pathogenic mechanism of parkin mutations", SOCIETY FOR NEUROSCIENCE ABSTRACTS, vol. 25, no. 1-2, 1999, pages 52 - Abstract 27.20, XP000884113 *
KITADA ET AL: "Mutations in the parkin gene cause autosomal recessive juvenile parkinsonism", NATURE,GB,MACMILLAN JOURNALS LTD. LONDON, vol. 392, no. 6676, 9 April 1998 (1998-04-09), pages 605 - 608, XP002108469, ISSN: 0028-0836 *
LEROY ET AL: "Deletions in the Parkin gene and genetic heterogeneity in a Greek family with early onset Parkinson's disease", HUMAN GENETICS,DE,BERLIN, vol. 103, no. 4, October 1998 (1998-10-01), pages 424 - 427, XP002108470 *
LÜCKING ET AL: "Homozygous deletions in parkin gene in European and North African families with autosomal recessive juvenile parkinsonism", LANCET THE,GB,LANCET LIMITED. LONDON, vol. 352, no. 9137, 24 October 1998 (1998-10-24), pages 1355 - 1356, XP002108466, ISSN: 0140-6736 *

Also Published As

Publication number Publication date
JP2003512026A (en) 2003-04-02
ATE396263T1 (en) 2008-06-15
CA2383564A1 (en) 2001-03-08
DE60038966D1 (en) 2008-07-03
WO2001016176A2 (en) 2001-03-08
EP1208200B1 (en) 2008-05-21
EP1081225A1 (en) 2001-03-07
EP1208200A2 (en) 2002-05-29
ES2304973T3 (en) 2008-11-01

Similar Documents

Publication Publication Date Title
EP0778886A4 (en) Transgenic animal expressing a familial form of human amyloid precursor protein
AU2001278084A1 (en) Model for alzheimer's disease and other neurodegenerative diseases
WO2004110472A3 (en) Fusion proteins
HUP0302114A2 (en) Liquid medicinal preparation containing erythropoietin protein, method for production and application
AU6840000A (en) Improvements in or relating to the production of animal feed
WO1999048482A3 (en) Smilagenin and anzurogenin-d for the treatment of alzheimer's disease
WO2005004814A3 (en) Sirt1 and genetic disorders
ZA200606834B (en) 1-Aminocyclohexane derivatives for the treatment of agitation and other behavioral disorders, especially those associated with Alzheimer's disease
AU2001229619A1 (en) Transgenic mouse model of human neurodegenerative disease
WO2002005634A3 (en) Transgenic animal and methods
AU4078900A (en) Methods for tracking the progression of alzheimer's disease and identifying treatments using transgenic mice
EP1029039A4 (en) Non-transgenic animal model of alzheimer's disease
AU2002222156A1 (en) Human protein differentially expressed in alzheimer's disease's brain
AU2001259471A1 (en) Evolution of plant disease response pathways to enable the development of plant based biological sensors and to develop novel disease resistance strategies
AU2001262726A1 (en) Transgenic non-human mammal and method of constructing the same, animal disease model and method of clarifying gene function
FR2766207B1 (en) CHIMERIC GENE ENCODING DROSOMYCIN, VECTOR CONTAINING THE SAME FOR THE TRANSFORMATION OF VEGETABLE CELLS AND OBTAINED TRANSFORMED PLANTS WITH DISEASE RESISTANCE
AU2001248839A1 (en) Remedies for interstitial pneumonia, method of constructing animal model of this disease and screening method with the use of the same
ATE396263T1 (en) TRANSGENIC ANIMAL MODEL FOR NEURODEGENERATIVE DISEASES
EP0652777A4 (en) METASTASE MODEL IN SMALL ANIMALS.
WO2002002755A3 (en) Regulation of human thimet oligopeptidase-like enzyme
WO2002000878A3 (en) Human msp1 mitochondrial dynamin, its msp1-x isoforms, and their therapeutic use
AU1581795A (en) Lure for facilitating the administration of drugs to certain animals, particularly dogs
AU2663800A (en) Use of natural substances to prevent the leaching of agrochemical active ingredients
AU5052899A (en) Genetic polymorphisms in the human neurokinin 1 receptor gene and their uses in diagnosis and treatment of diseases
AU1604400A (en) The use of beta-glucosidase to enhance disease resistance and resistance to insects in crop plants

Legal Events

Date Code Title Description
AK Designated states

Kind code of ref document: A2

Designated state(s): CA JP US

AL Designated countries for regional patents

Kind code of ref document: A2

Designated state(s): AT BE CH CY DE DK ES FI FR GB GR IE IT LU MC NL PT SE

WWE Wipo information: entry into national phase

Ref document number: 09830703

Country of ref document: US

121 Ep: the epo has been informed by wipo that ep was designated in this application
DFPE Request for preliminary examination filed prior to expiration of 19th month from priority date (pct application filed before 20040101)

Free format text: (EXCEPT US)

AK Designated states

Kind code of ref document: A3

Designated state(s): CA JP US

AL Designated countries for regional patents

Kind code of ref document: A3

Designated state(s): AT BE CH CY DE DK ES FI FR GB GR IE IT LU MC NL PT SE

WWE Wipo information: entry into national phase

Ref document number: 2000956461

Country of ref document: EP

WWE Wipo information: entry into national phase

Ref document number: 2383564

Country of ref document: CA

WWP Wipo information: published in national office

Ref document number: 2000956461

Country of ref document: EP

WWG Wipo information: grant in national office

Ref document number: 2000956461

Country of ref document: EP